 - known sensitizing EGFR mutations or ALK gene rearrangements if the participant has not yet tried EGFR or ALK inhibitor therapies. If the potential participants biopsy did not allow for gene analysis inconclusive, not enough tissue, the patient is considered eligible for the study. Enrollment on this clinical trial after progression on targeted therapy is allowed 